TY - JOUR
T1 - Uncertainties and challenges in surgical and transcatheter tricuspid valve therapy
T2 - A state-of-the-art expert review
AU - Chang, Chun Chin
AU - Veen, Kevin M.
AU - Hahn, Rebecca T.
AU - Bogers, Ad J.J.C.
AU - Latib, Azeem
AU - Oei, Frans B.S.
AU - Abdelghani, Mohammad
AU - Modolo, Rodrigo
AU - Ho, Siew Yen
AU - Abdel-Wahab, Mohamed
AU - Fattouch, Khalil
AU - Bosmans, Johan
AU - Caliskan, Kadir
AU - Taramasso, Maurizio
AU - Serruys, Patrick W.
AU - Bax, Jeroen J.
AU - Van Mieghem, Nicolas M.D.A.
AU - Takkenberg, Johanna J.M.
AU - Lurz, Philip
AU - Modine, Thomas
AU - Soliman, Osama
N1 - Funding Information:
This work is supported by The Euro Heart Foundation.
Publisher Copyright:
© 2019 Published on behalf of the European Society of Cardiology. All rights reserved. © The Author(s) 2019.
PY - 2020/5/21
Y1 - 2020/5/21
N2 - Tricuspid regurgitation (TR) is a frequent and complex problem, commonly combined with left-sided heart disease, such as mitral regurgitation. Significant TR is associated with increased mortality if left untreated or recurrent after therapy. Tricuspid regurgitation was historically often disregarded and remained undertreated. Surgery is currently the only Class I Guideline recommended therapy for TR, in the form of annuloplasty, leaflet repair, or valve replacement. As growing experience of transcatheter therapy in structural heart disease, many dedicated transcatheter tricuspid repair or replacement devices, which mimic well-established surgical techniques, are currently under development. Nevertheless, many aspects of TR are little understood, including the disease process, surgical or interventional risk stratification, and predictors of successful therapy. The optimal treatment timing and the choice of proper surgical or interventional technique for significant TR remain to be elucidated. In this context, we aim to highlight the current evidence, underline major controversial issues in this field and present a future roadmap for TR therapy.
AB - Tricuspid regurgitation (TR) is a frequent and complex problem, commonly combined with left-sided heart disease, such as mitral regurgitation. Significant TR is associated with increased mortality if left untreated or recurrent after therapy. Tricuspid regurgitation was historically often disregarded and remained undertreated. Surgery is currently the only Class I Guideline recommended therapy for TR, in the form of annuloplasty, leaflet repair, or valve replacement. As growing experience of transcatheter therapy in structural heart disease, many dedicated transcatheter tricuspid repair or replacement devices, which mimic well-established surgical techniques, are currently under development. Nevertheless, many aspects of TR are little understood, including the disease process, surgical or interventional risk stratification, and predictors of successful therapy. The optimal treatment timing and the choice of proper surgical or interventional technique for significant TR remain to be elucidated. In this context, we aim to highlight the current evidence, underline major controversial issues in this field and present a future roadmap for TR therapy.
KW - Heart failure
KW - Imaging
KW - Outcome
KW - Risk
KW - Treatment
KW - Tricuspid regurgitation
KW - Tricuspid valve
UR - http://www.scopus.com/inward/record.url?scp=85074432545&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074432545&partnerID=8YFLogxK
U2 - 10.1093/eurheartj/ehz614
DO - 10.1093/eurheartj/ehz614
M3 - Review article
C2 - 31511897
AN - SCOPUS:85074432545
SN - 0195-668X
VL - 41
SP - 1932
EP - 1940
JO - European heart journal
JF - European heart journal
IS - 20
ER -